This listing of claims reflects the claims currently pending in the present

application.

1. (Currently Amended) A bio-compatible product for delivery of a

pharmaceutically active agent to a patient in need of same, comprising:

a mass of bio-compatible, biodegradable anionic or cationic carrier;

a pharmaceutically active agent which is cationic when the carrier is

anionic and is anionic when the carrier is cationic, wherein said active agent is ionically

linked to said carrier, thereby forming a mass of carrier/active agent combination; and

a bio-compatible envelope with exterior walls formed from a microporous

film, said envelope having an interior hollow delimited by said exterior walls, said

envelope enclosing means for enclosing said mass of carrier/active agent combination

within said hollow, said film enclosing means including at least one outwardly-directed

surface having a predetermined permeation gradient for the passage therethrough of

said pharmaceutically active agent.

2. (Currently amended) A bio-compatible product for delivery of a

pharmaceutically active agent to a patient in need of same, comprising:

a mass of bio-compatible, biodegradable anionic or cationic carrier;

a pharmaceutically active agent which is cationic when the carrier is

anionic and is anionic when the carrier is cationic, wherein said active agent is ionically

linked to said carrier, thereby forming a mass of carrier/active agent combination; and

2

Responding to Office Action of February 8, 2005

a bio-compatible, biodegradable envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said mass of carrier/active agent combination within said hollow, said enclosing means including at least one outwardly directed side exterior walls including a pair of substantially planar, parallel, opposed walls.

- (Currently amended) The bio-compatible product in accordance 3. with claim 2. wherein said envelope bio-compatible, biodegradable enclosing means has a predetermined permeation gradient for the passage therethrough of said pharmaceutically active agent, said opposed walls being conjoined at respective peripheral edges thereof to form said envelope.
- 4. (Previously presented) The bio-compatible product in accordance with claim 1, wherein the carrier is an anionic carrier.
- 5. (Previously presented) The bio-compatible product in accordance with claim 1, wherein the active agent is a cationic agent.
- (Previously presented) The bio-compatible product in accordance 6. with claim 5, wherein the active agent is selected from the group consisting of cationic analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents and hemostatic agents.
- (Previously presented) The bio-compatible product in accordance 7. with claim 4, wherein the anionic carrier is an oxidized regenerated cellulose carrier.

'Appln. Serial No. 10/029,506 Response dated April 22, 2005 Responding to Office Action of February 8, 2005

- 8. (Previously presented) The bio-compatible product in accordance with claim 7, wherein the anionic carrier is an oxidized regenerated cellulose fabric.
- 9. (Previously presented) The bio-compatible product in accordance with claim 8, wherein the active agent is a cationic agent.
- 10. (Previously presented) The bio-compatible product in accordance with claim 9, wherein the active agent is selected from the group consisting of cationic analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents, anticholinergics, antidepressants, antihistamines, antidiabetics, anticonvulsants, antimigraines, antineoplastics, antimalarials, immunosuppressants, cardiovascular drugs, growth factors and hemostatic agents.
- 11. (Currently amended) The bio-compatible product in accordance with claim 1, wherein said film the enclosing means is a non-biodegradeable polymer film.
- 12. (Currently amended) The bio-compatible product in accordance with claim 11, wherein said polymer is selected from the group consisting of polyethylene, polypropylene, mixtures thereof and copolymers of the constituent monomers thereof, said film a microporous polymer having a pore size of between 0.01 and 1000 microns.
- 13. (Currently amended) The bio-compatible product in accordance with claim 12, wherein said <u>film</u> microporous polymer has a pore size of between 0.1 and 500 microns.

Appln. Serial No. 10/029,506
Response dated April 22, 2005
Responding to Office Action of February 8, 2005

- 14. (Currently amended) The bio-compatible product in accordance with claim 13, wherein said <u>film</u> microperous polymer has a pore size of between 0.1 and 50 microns.
- 15. (Currently amended) The bio-compatible product in accordance with claim 14, wherein said <u>film</u> microperous polymer has a pore size of between 0.1 and 5 microns.
- 16. (Currently amended) The bio-compatible product in accordance with claim 15, wherein said <u>film microperous polymer</u> has a pore size of between 0.1 and 1 microns.
- 17. (Currently amended) The bio-compatible product in accordance with claim 1, wherein the enclosing means is a polymer <u>said</u> film <u>is</u> selected from the group consisting of PLA, PLG, mixtures thereof and copolymers of the constituent monomers thereof.
- 18. (Previously presented) The bio-compatible product in accordance with claim 2, wherein the carrier is an anionic carrier.
- 19. (Previously presented) The bio-compatible product in accordance with claim 18, wherein the active agent is a cationic agent.
- 20. (Previously presented) The bio-compatible product in accordance with claim 19, wherein the active agent is selected from the group consisting of cationic analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents, anticholinergics, antidepressants, antihistamines, antidiabetics, anticonvulsants,

antimigraines, antineoplastics, antimalarials, immunosuppressants, cardiovascular drugs, growth factors and hemostatic agents.

- 21. (Previously presented) The bio-compatible product in accordance with claim 20, wherein the anionic carrier is an oxidized regenerated cellulose carrier.
- 22. (Previously presented) The bio-compatible product in accordance with claim 21, wherein the anionic carrier is an oxidized regenerated cellulose fabric.
- 23. (Previously presented) The bio-compatible product in accordance with claim 22, wherein the active agent is selected from the group consisting of cationic analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents and hemostatic agents.
- 24. (Currently amended) The bio-compatible product in accordance with claim 2, wherein the enclosing means said film is a polymer selected from the group consisting of PLA, PLG, mixtures thereof and copolymers of the constituent monomers thereof.
- 25. (Currently amended) A bio-compatible product for delivery of a pharmaceutically active agent to a patient in need of same, comprising:
- a <u>mass of</u> bio-compatible, biodegradable anionic carrier which is an oxidized regenerated cellulose fabric;

a cationic pharmaceutically active agent which is ionically linked to said carrier, thereby forming a mass of carrier/active agent combination; said cationic pharmaceutically active agent being selected from the group consisting of cationic

analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents, anticholinergics, antidepressants, antihistamines, antidiabetics, anticonvulsants, antimigraines, antineoplastics, antimalarials, immunosuppressants, cardiovascular drugs, growth factors and hemostatic agents and

a bio-compatible envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said carrier/active agent combination, said enclosing means film being made from a polymer selected from the group consisting of polyethylene, polypropylene, mixtures thereof and copolymers of the constituent monomers thereof, said enclosing means including at least one outwardly directed surface film having a predetermined permeation gradient for the passage therethrough of said pharmaceutically active agent.

- 26. (Cancelled.)
- 27. (Currently amended) The bio-compatible product in accordance with claim 3, wherein the <u>film</u> enclosing means is a-microporous polymer film.
- 28. (Previously presented) The bio-compatible product in accordance with claim 27, wherein the carrier is an anionic carrier.
- 29. (Previously presented) The bio-compatible product in accordance with claim 28, wherein the active agent is a cationic agent.
- 30. (Previously presented) The bio-compatible product in accordance with claim 29, wherein the active agent is selected from the group consisting of cationic

analgesics, antibiotics, antimicrobials, antivirals, anti-inflammatory agents, anticholinergics, antidepressants, antihistamines, antidiabetics, anticonvulsants, antimigraines, antineoplastics, antimalarials, immunosuppressants, cardiovascular drugs and hemostatic agents.

- 31. (Previously presented) The bio-compatible product in accordance with claim 28, wherein the anionic carrier is an oxidized regenerated cellulose carrier.
- 32. (Previously presented) The bio-compatible product in accordance with claim 31, wherein the anionic carrier is an oxidized regenerated cellulose fabric.
- 33. (Previously presented) The bio-compatible product in accordance with claim 32, wherein the active agent is a cationic agent.
- 34. (Currently amended) The bio-compatible product in accordance with claim 27, wherein said <u>film</u> microporous polymer has a pore size of between 0.01 and 1000 microns.
- 35. (Currently amended) The bio-compatible product in accordance with claim 34, wherein said <u>film</u> microporous polymer has a pore size of between 0.1 and 500 microns.
- 36. (Currently amended) The bio-compatible product in accordance with claim 35, wherein said <u>film microporous polymer</u> has a pore size of between 0.1 and 50 microns.

Appln. Serial No. 10/029,506
Response dated April 22, 2005
Responding to Office Action of February 8, 2005

37. (Currently amended) The bio-compatible product in accordance with claim 36, wherein said <u>film</u> microporous polymer has a pore size of between 0.1 and 5 microns.

38. (Currently amended) The bio-compatible product in accordance with claim 37, wherein said <u>film</u> microporous polymer has a pore size of between 0.1 and 1 microns.

39. (Currently amended) The bio-compatible product in accordance with claim 3, wherein said <u>film</u> enclosing means is made from a polymer selected from the group consisting of PLA, PLG, mixtures thereof and copolymers of the constituent monomers thereof.

40. (Currently amended) A bio-compatible product for delivery of a pharmaceutically active agent to a patient in need of same, comprising:

a mass of bio-compatible, biodegradable anionic or cationic carrier;

a pharmaceutically active agent which is cationic when the carrier is anionic and is anionic when the carrier is cationic, wherein said active agent is ionically linked to said carrier, thereby forming a <u>mass of</u> carrier/active agent combination;

a bio-compatible envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said mass of carrier/active agent combination, said enclosing means including at least one an outwardly directed surface of at least

one of said exterior walls having a predetermined permeation gradient for the passage therethrough of said pharmaceutically active agent; and

a further carrier layer disposed located on said at-least-one outwardly directed surface exterior to said hollow of said enclosing means.

41. (Currently amended) A bio-compatible product for delivery of a pharmaceutically active agent to a patient in need of same, comprising:

a mass of bio-compatible, biodegradable anionic or cationic carrier;

a pharmaceutically active agent which is cationic when the carrier is anionic and is anionic when the carrier is cationic, wherein said active agent is ionically linked to said carrier, thereby forming a mass of carrier/active agent combination;

a bio-compatible, biodegradable envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said carrier/active agent combination within said hollow, said enclosing means including at least one outwardly directed side exterior walls including a pair of substantially planar, parallel, opposed walls; and

a further carrier layer located disposed on said at least one an outwardly directed side of at least one of said walls exterior to said hollow of said enclosing means.

42. (Currently amended) A bio-compatible product for delivery of a pharmaceutically active agent to a patient in need of same, comprising:

a mass of bio-compatible, biodegradable anionic or cationic carrier;

a pharmaceutically active agent which is cationic when the carrier is anionic and is anionic when the carrier is cationic, wherein said active agent is ionically linked to said carrier, thereby forming a mass of carrier/active agent combination;

a bio-compatible, biodegradable envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said carrier/active agent combination within said hollow, said exterior walls including a pair of substantially planar, parallel, opposed walls enclosing means including at least one outwardly directed side and having a predetermined permeation gradient for the passage therethrough of said pharmaceutically active agent; and

a further carrier layer <u>disposed</u> located on said at least one <u>an</u> outwardly facing surface of <u>each of said walls</u> said enclosing means.

43. (Currently amended) A method of administering a pharmaceutically active agent to the tissue surface of a subject in need of same, comprising the step of contacting said tissue surface with a bio-compatible delivery product having a bio-compatible, biodegradable anionic or cationic carrier, a pharmaceutically active agent which is cationic when the carrier is anionic and is anionic when the carrier is cationic, wherein said active agent is ionically linked to said carrier, thereby forming a carrier/active agent combination, said carrier being disposed within a bio-compatible, non-biodegradable envelope with exterior walls formed from a microporous film, said

Appln. Serial No. 10/029,506 Response dated April 22, 2005

Responding to Office Action of February 8, 2005

envelope having an interior hollow delimited by said exterior walls, said envelope

enclosing means for enclosing said carrier/active agent combination having at least one

outwardly directed surface said film having a predetermined permeation gradient for the

passage therethrough of said at least one pharmaceutically active agent, said

administration of said pharmaceutically active agent being dependent on the

permeability of said film enclosing means.

44. (Currently amended) A method of administering a pharmaceutically

active agent to the tissue surface of a subject in need of same, comprising the step of

contacting said tissue surface with a bio-compatible delivery product having a bio-

compatible, biodegradable anionic or cationic carrier, a pharmaceutically active agent

which is cationic when the carrier is anionic and is anionic when the carrier is cationic,

wherein said active agent is ionically linked to said carrier, thereby forming a

carrier/active agent combination, said carrier being disposed within a bio-compatible,

biodegradable envelope with exterior walls formed from a microporous film, said

envelope having an interior hollow delimited by said exterior walls said envelope

enclosing means for enclosing said carrier/active agent combination having at least one

outwardly directed side, said administration of said pharmaceutically active agent being

dependent on the rate of bio-degradability of the film enclosing means.

45. (Currently amended) A method of administering a pharmaceutically

active agent to the tissue surface of a subject in need of same, comprising the step of

contacting said tissue surface with a bio-compatible delivery product having a bio-

12

means.

compatible, biodegradable anionic or cationic carrier, a pharmaceutically active agent which is cationic when the carrier is anionic and is anionic when the carrier is cationic, wherein said active agent is ionically linked to said carrier, thereby forming a carrier/active agent combination, said carrier being disposed within a bio-compatible, biodegradable envelope with exterior walls formed from a microporous film, said envelope having an interior hollow delimited by said exterior walls, said envelope enclosing means for enclosing said carrier/active agent combination having at least one outwardly directed—side, said film bio-compatible, biodegradable—enclosing means having a predetermined permeation gradient for the passage therethrough of said pharmaceutically active agent, said administration of said pharmaceutically active agent being dependent on the rates of bio-degradability and permeability of the film enclosing